Stephen Arnovitz

Predisposition to hematopoietic malignancies by deleterious germline CHEK2 variants

Tcf-1 promotes genomic instability and T cell transformation in response to aberrant β-catenin activation

Wnt–β-catenin activation epigenetically reprograms Treg cells in inflammatory bowel disease and dysplastic progression

TCF-1 and HEB cooperate to establish the epigenetic and transcription profiles of CD4+CD8+ thymocytes

Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia

FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N 6 -Methyladenosine RNA Demethylase

miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia

Eradication of Acute Myeloid Leukemia with FLT3 Ligand–Targeted miR-150 Nanoparticles

PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the <i>MLL</i> -Rearranged Disease

Fto Plays an Oncogenic Role in Acute Myeloid Leukemia As a N6-Methyladenosine RNA Demethylase

Overexpression and knockout of miR-126 both promote leukemogenesis

Brca1 deficiency causes bone marrow failure and spontaneous hematologic malignancies in mice

<i>TET1</i> plays an essential oncogenic role in <i>MLL</i> -rearranged leukemia

miR-9 is an essential oncogenic microRNA specifically overexpressed in <i>mixed lineage leukemia</i> –rearranged leukemia

PBX3 is an important cofactor of HOXA9 in leukemogenesis

Blockade of miR-150 Maturation by MLL-Fusion/MYC/LIN-28 Is Required for MLL-Associated Leukemia

miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia

Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML

miR-495 is a tumor-suppressor microRNA down-regulated in <i>MLL</i> -rearranged leukemia